Randomized clinical trials have shown no significant benefit from checkpoint blockade in an unselected cohort.410 KEYNOTE-028 was a basket trial in which PD-L1 positive tumors were treated with the anti-PD1 antibody pembrolizumab.411 Unfortunately, PDAC showed the lowest response rate of all tumor types studied. The gene discussed is PDCD1; the disease is neoplasm.